Market Research Logo

West Nile Virus Infections - Pipeline Review, H2 2016

West Nile Virus Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘West Nile Virus Infections - Pipeline Review, H2 2016’, provides an overview of the West Nile Virus Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for West Nile Virus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for West Nile Virus Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of West Nile Virus Infections
    • The report reviews pipeline therapeutics for West Nile Virus Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved West Nile Virus Infections therapeutics and enlists all their major and minor projects
    • The report assesses West Nile Virus Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for West Nile Virus Infections
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for West Nile Virus Infections
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding West Nile Virus Infections pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    West Nile Virus Infections Overview
    Therapeutics Development
    Pipeline Products for West Nile Virus Infections - Overview
    Pipeline Products for West Nile Virus Infections - Comparative Analysis
    West Nile Virus Infections - Therapeutics under Development by Companies
    West Nile Virus Infections - Therapeutics under Investigation by Universities/Institutes
    West Nile Virus Infections - Pipeline Products Glance
    Clinical Stage Products
    Early Stage Products
    West Nile Virus Infections - Products under Development by Companies
    West Nile Virus Infections - Products under Investigation by Universities/Institutes
    West Nile Virus Infections - Companies Involved in Therapeutics Development
    CEL-SCI Corporation
    Hemispherx Biopharma, Inc.
    Kineta, Inc.
    Nanotherapeutics, Inc.
    Plex Pharmaceuticals, Inc.
    West Nile Virus Infections - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    Alferon LDO - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BG-323 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CEL-1000 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FDX-000 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HydroVax-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    interferon alfa-n3 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KIN-1148 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KIN-1400 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody for West Nile Virus Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rintatolimod - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RL-15A - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit NS2B-NS3 Protease for Dengue, Zika and West Nile Virus Infection - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Viral Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit NS3 Protease for Dengue and West Nile Virus Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptide for Dengue Virus and West Nile Virus Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Tatbeclin-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    West Nile virus vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    West Nile virus vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    West Nile Virus Infections - Dormant Projects
    West Nile Virus Infections - Product Development Milestones
    Featured News & Press Releases
    Jul 06, 2015: NIH-funded vaccine for West Nile Virus enters human clinical trials
    May 05, 2014: Alferon N Effective Against MERS Virus In-Vitro
    Sep 12, 2013: Hemispherx Announces Initial Test Results in Biosecurity/Biodefense Arena
    Sep 06, 2011: Hemispherx Enters Into Strategic Alliance With Armada Health Care For Alferon N Injection
    Apr 20, 2010: Kineta Scientist to Present Novel Antiviral Research Findings at International Conference
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for West Nile Virus Infections, H2 2016
    Number of Products under Development for West Nile Virus Infections - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    West Nile Virus Infections - Pipeline by CEL-SCI Corporation, H2 2016
    West Nile Virus Infections - Pipeline by Hemispherx Biopharma, Inc., H2 2016
    West Nile Virus Infections - Pipeline by Kineta, Inc., H2 2016
    West Nile Virus Infections - Pipeline by Nanotherapeutics, Inc., H2 2016
    West Nile Virus Infections - Pipeline by Plex Pharmaceuticals, Inc., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    West Nile Virus Infections - Dormant Projects, H2 2016
    West Nile Virus Infections - Dormant Projects (Contd..1), H2 2016
    West Nile Virus Infections - Dormant Projects (Contd..2), H2 2016
    List of Figures
    Number of Products under Development for West Nile Virus Infections, H2 2016
    Number of Products under Development for West Nile Virus Infections - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report